Glycerin

Glycerin

SCHEMBL2236339

CC(O)CO.CCOCC.OCC(O)CO

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.53
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
USP2 O75604 1/20 0.39
TSHR P16473 4/20 0.38
HSD17B10 Q99714 1/20 0.37
THRB P10828 1/20 0.33
KDM4E B2RXH2 2/20 0.31
DUSP3 P51452 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycerin SCHEMBL490858 0.92 LMNA (0.56) TDP1ALDH1A1LMNAUSP2TSHR
Glycerin SCHEMBL8080968 0.92 LMNA (0.56) TDP1ALDH1A1LMNAUSP2TSHR
Propylene Glycol SCHEMBL18285762 0.92 TDP1 (0.62) TDP1ALDH1A1LMNAUSP2TSHR
Propylene Glycol SCHEMBL35797 0.92 TDP1 (0.62) TDP1ALDH1A1LMNAUSP2TSHR
Glycerin SCHEMBL30753 0.92 LMNA (0.56) TDP1ALDH1A1LMNAUSP2TSHR
Glycerin SCHEMBL6426113 0.92 LMNA (0.56) TDP1ALDH1A1LMNAUSP2TSHR
Propylene Glycol SCHEMBL4936361 0.92 TDP1 (0.62) TDP1ALDH1A1LMNAUSP2TSHR
Glycerin SCHEMBL11595153 0.89 LMNA (0.53) TDP1ALDH1A1LMNAUSP2TSHR
Propylene Glycol SCHEMBL6135352 0.89 TDP1 (0.59) TDP1ALDH1A1LMNAUSP2TSHR
Glycerin SCHEMBL4723284 0.89 LMNA (0.53) TDP1ALDH1A1LMNAUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106659671-B Composition in the form of an emulsion 莱雅公司 2021-11-16 CN claimed
CN-105979929-B Composition in the form of an emulsion 莱雅公司 2020-08-21 CN claimed
CN-106659672-B Composition in the form of an emulsion 莱雅公司 2020-04-21 CN claimed
EP-0575653-B1 Process for the increase of strength of the highly permeable capillary hollow membranes SAECHSISCHE KUNSTSEIDEN GMBH (DE) 1996-03-13 EP claimed
US-20240024221-A1 COMPOSITION FOR BRIGHTENING AND/OR WHITENING KERATIN MATERIALS L'OREAL (FR) 2024-01-25 US disclosed
CN-117098807-A Polymer structure comprising a base plastic with a hydration layer to avoid biofilm formation 纳米及先进材料研发院有限公司 2023-11-21 CN disclosed
WO-2023194511-A1 COMPOSITION FOR THE COSMETIC TREATMENT OF KERATIN FIBERS BIOSYNTHIS (FR) 2023-10-12 WO disclosed
CN-116669686-A Composition for lightening and/or whitening keratin materials 莱雅公司 2023-08-29 CN disclosed
EP-4175605-A1 TWO-PHASE COMPOSITION COMPRISING AN ALKYLPOLYGLYCOSIDE SURFACTANT, A PARTICULAR DIOL AND AN ALKANE, ESTER OR ETHER COMPOUND COMPRISING FROM 15 TO 30 CARBON ATOMS L'OREAL (FR) 2023-05-10 EP disclosed
WO-2022133715-A1 COMPOSITION FOR BRIGHTENING AND/OR WHITENING KERATIN MATERIALS L'OREAL (FR) 2022-06-30 WO disclosed
WO-2022003000-A1 TWO-PHASE COMPOSITION COMPRISING AN ALKYLPOLYGLYCOSIDE SURFACTANT, A PARTICULAR DIOL AND AN ALKANE, ESTER OR ETHER COMPOUND COMPRISING FROM 15 TO 30 CARBON ATOMS L'OREAL (FR) 2022-01-06 WO disclosed
CN-106659671-B Composition in the form of an emulsion 莱雅公司 2021-11-16 CN disclosed
EP-2872112-A2 TWO-PHASE COMPOSITION CONTAINING AN ALKYLPOLYGLUCOSIDE AND AN ESTER WITH A MELTING POINT OF LESS THAN 10°C L'Oréal (FR) 2015-05-20 EP disclosed
WO-2015062993-A1 TWO-PHASE COMPOSITION COMPRISING A FATTY ACID ESTER OF SUGAR OR A LIQUID ALKYL POLYGLUCOSIDE, WITH AN HLB < 8, AND A C8-C18 BRANCHED ALKANE L'OREAL (FR) 2015-05-07 WO disclosed
WO-2015062016-A1 COMPOSITION IN FORM OF AN EMULSION L'OREAL (FR) 2015-05-07 WO disclosed
WO-2014013420-A2 TWO-PHASE COMPOSITION CONTAINING AN ALKYLPOLYGLUCOSIDE AND AN ESTER WITH A MELTING POINT OF LESS THAN 10°C L'OREAL (FR) 2014-01-23 WO disclosed
EP-2353587-A2 Antimicrobial compositions and methods 3M Innovative Properties Co. (US) 2011-08-10 EP disclosed
WO-2010069995-A1 SILICONE-FREE TRANSPARENT TWO-PHASE COMPOSITION L'OREAL (FR) 2010-06-24 WO disclosed
US-7078687-B2 Thin film analyzing method FUJI PHOTO FILM CO., LTD. (JP) 2006-07-18 US disclosed
US-20040232330-A1 Thin film analyzing method FUJI PHOTO FILM CO., LTD. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024221-A1 COMPOSITION FOR BRIGHTENING AND/OR WHITENING KERATIN MATERIALS KRT18, LMNB2, LMNB1 TDP1 4176/4885ALDH1A1 2852/4885LMNA 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.